Female Obesity Cohort and Intervention Study Group (MOCART Study Group) (MOCART)
A Prospective Observational Trial of Factors Involved in the Intergenerational Transmission of the Non-communicable Disorders - Female Obesity Cohort and Intervention Study Group.
調査の概要
詳細な説明
The available epidemiological data clearly indicate a significant increase in the percentage of people with obesity and the metabolic syndrome in the population of women of reproductive age. These diseases predispose to the onset of type 2 diabetes at a young age and accelerate the risk of cardiovascular diseases, while in pregnant population they constitute a serious risk factor for gestational diabetes.
Recent decades have brought a growing amount of evidence from prospective studies indicating the adverse impact of gestational diabetes on the health prognosis of the mother and her child. In the short-term perspective, hyperglycemia in pregnancy constitutes a risk factor for numerous maternal-fetal complications, in particular hypertensive diseases in pregnancy, excessive fetal growth, intrapartum complications induced by excessive birth weight of the newborn, which can result in intrapartum neonatal asphyxia or maternal postpartum haemorrhage. Gestational diabetes is also associated with an increased risk of fetal intrauterine death in late pregnancy, during delivery or postpartum.
However, there is growing evidence of the adverse effects of gestational diabetes on long-term health outcomes of the mother and her offspring, even when glucose tolerance disorders are resolved after delivery. Hyperglycemia detected in pregnancy is a strong risk factor for the development of type 2 diabetes within several years after experiencing a complicated pregnancy. Moreover, maternal hyperglycemia has been shown to adversely affect the long-term risk of obesity, metabolic syndrome, pre-diabetes, and type 2 diabetes in the offspring of this pregnant population. This relationship is so clear that it is the exposure of the fetus to the abnormal intrauterine metabolic environment that is considered to be one of the leading causes of the significantly increased prevalence of the aforementioned civilization diseases among children and adolescents.
The authors of the study expect that the obtained results will provide important data enabling early identification of the population that can benefit most measurably from the diagnosis and possible treatment of conditions predisposing to the non-communicable diseases. The authors believe, that this study will identify specific maternal characteristics that could be targets for individualized interventions modifying risk factors of civilization diseases in mothers and their offspring. The authors expect that the measurable effect of the research will be achievable in the short term - in the form of reduction of maternal-fetal complications characteristic of pregnancy complicated with obesity and / or gestational diabetes (maternal "diabesity"), and in the long term - in the form of improvement of the incidence rates of non-communicable disorders in the population of pregnant women of a risk profile similar to this presented by the cohort included in the study.
Research objectives:
- identification of epigenetic risk factors of intergenerational glucose tolerance disorders and examining the possibility of their modification so as to break the intergenerational "vicious circle" of metabolic syndrome and lifestyle diseases resulting from it;
- identification of mechanisms responsible for the intergenerational transmission of classic and "new" risk factors of non-communicable diseases;
- gather information for future trials on development and evaluation of interventions aimed at reducing the effects of the intergenerational "vicious circle" of obesity, insulin resistance and diseases related to lifestyle.
The protocol includes the following visits:
V0 - recruitment, V1 - gestational age 28-32 weeks, V2 - gestational age 36-38 weeks, V3 - delivery, V4 - six weeks postpartum, V5 - six months postpartum
At the V0, the researchers will collect detailed information concerning demographics, anthropometrics, past diseases, pregnancy-related conditions, lifestyle and dietary habits
At the V1, V2, V4 and V5, the researchers collect data regarding maternal glucose levels and body weight, perform noninvasive tests of cardiovascular function and collect biological material to be aliquoted, frozen and stored for further examination of biomarkers of oxidative stress, fat tissue function, inflammation, insulin resistance, clotting system, cardiometabolic risk; also information regarding fetal growth (V1,V2) and child's anthropometrics and development (V4, V5) will be collected.
At the V3, the researchers collect a detailed information regarding delivery and neonatal anthropometrics, and collect samples of placenta and cord blood to be aliquoted, frozen and stored for further examination (see above).
At the V6, the researchers collect information regarding maternal dietary and lifestyle habits, perform noninvasive tests of cardiovascular function and collect biological material to be aliquoted, frozen and stored for further examination of biomarkers of oxidative stress, fat tissue function, inflammation, insulin resistance, clotting system, cardiometabolic risk.
研究の種類
入学 (予想される)
連絡先と場所
研究連絡先
- 名前:Ewa Wender-Ożegowska, prof.
- 電話番号:+4861859302
- メール:klinrozrod.gpsk.um@gmail.com
研究場所
-
-
-
Poznan、ポーランド、60-535
- 募集
- Department of Reproduction, Poznan University of Medical Sciences
-
コンタクト:
- Ewa Wender-Ożegowska, prof.
- 電話番号:+4861659302
- メール:klinrozrod@gpsk.ump.edu.pl
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- a woman in a singleton pregnancy referred to the Department of Reproduction, Poznan University of Medical Sciences
- maternal BMI (body mass index): 27 kg/m2 or above
- hyperglycemia detected in pregnancy according to the Polish Diabetes Association criteria, 2017
- delivery in the University Hospital
Exclusion Criteria:
- fetal malformation
- any serious maternal conditions that might hamper patient's participation in the tiral
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
---|---|
MOZART_SG
Women treated for hyperglycemia in pregnancy.
Observational data are to be collected at follow-up visits during pregnancy, at delivery and postpartum.
|
Dietary and lifestyle modification recommended for pregnant women with hyperglycemia detected in pregnancy.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
maternal weight before delivery
時間枠:measured at term, within a week before delivery
|
kg
|
measured at term, within a week before delivery
|
maternal weight in the early pregnancy
時間枠:measured after a viable pregnancy confirmed until a gestational age of 12 weeks
|
kg
|
measured after a viable pregnancy confirmed until a gestational age of 12 weeks
|
birth weight
時間枠:neonate's weight measured immediately after birth
|
g
|
neonate's weight measured immediately after birth
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
maternal blood pressure at the term
時間枠:measured at term, within a week before delivery
|
mmHg
|
measured at term, within a week before delivery
|
average maternal fasting glucose at the term
時間枠:measured seven times within two weeks before delivery
|
mg/dl
|
measured seven times within two weeks before delivery
|
average maternal postprandial glucose at the term
時間枠:measured one hour after main meals, twenty-one times within two weeks before delivery
|
mg/dl
|
measured one hour after main meals, twenty-one times within two weeks before delivery
|
maternal HbA1c at the term
時間枠:glycated haemoglobin measured within a month before delivery
|
percent [%]
|
glycated haemoglobin measured within a month before delivery
|
協力者と研究者
捜査官
- スタディディレクター:Ewa Wender-Ożegowska, prof.、Head of the Department of Reproduction
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 102/19
- 525/17 (その他の識別子:Poznan University of Medical Sciences - Bioethics Board)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
妊娠中の高血圧の臨床試験
-
Hospital Universitario Doctor Pesetわからない
-
Food and Drug Administration (FDA)United States Department of Defense; National Eye Institute (NEI); United States Naval Medical...完了
-
Mahmoud Hussein Bahr積極的、募集していない( 4 in 1 ブロック ) & ( 内転筋管ブロック ) による鎮痛効果の比較エジプト
-
Food and Drug Administration (FDA)National Eye Institute (NEI)完了
-
Assistance Publique - Hôpitaux de Paris完了
-
Meshalkin Research Institute of Pathology of Circulationまだ募集していませんin vivo 大動脈の強度特性 | インビトロでの大動脈の強度特性 | インビトロおよびインビトロの大動脈強度特性の回帰モデルロシア連邦
-
Maastricht University Medical Center引きこもった
-
Queen Mary University of London完了このプロジェクトの最初の目的は、利用可能な Mutanome データから選択されたネオエピトープ候補の in vitro 検証を実行することです。イギリス
Monitoring and lifestyleの臨床試験
-
Oxford Biomedical Technologies, Inc.募集
-
Royal Brompton & Harefield NHS Foundation TrustUniversity of Oxford; National Institute for Health Research, United Kingdom完了
-
Universiti Sultan Zainal Abidin募集